Literature DB >> 25062638

Lentiviral gene transduction of mouse and human hematopoietic stem cells.

Niek P van Til1, Gerard Wagemaker.   

Abstract

Lentiviral vectors can be used to genetically modify a broad range of cells. Hematopoietic stem cells (HSCs) are particularly suitable for lentiviral gene augmentation, because these cells can be enriched with relative ease from mouse bone marrow and human hematopoietic sources, and in principle require relatively limited cell numbers to completely reconstitute the hematopoietic system in vivo. Furthermore, lentiviral vectors are very efficient if pseudotyped with broad tropism envelope proteins. This chapter focuses on gene modification by the use of self-inactivating third-generation human immunodeficiency virus-derived lentiviral vectors for ex vivo HSC modification for both mouse and human application.

Entities:  

Mesh:

Year:  2014        PMID: 25062638     DOI: 10.1007/978-1-4939-1133-2_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

Review 1.  Lentiviral hematopoietic stem cell gene therapy in inherited metabolic disorders.

Authors:  Gerard Wagemaker
Journal:  Hum Gene Ther       Date:  2014-09-17       Impact factor: 5.695

Review 2.  The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.

Authors:  Jake Moscarelli; David Zahavi; Rachael Maynard; Louis M Weiner
Journal:  Transplant Cell Ther       Date:  2022-07-03

3.  Generation and Hematopoietic Differentiation of Mesenchymal Stromal/Stem Cell-Derived Induced Pluripotent Stem Cell Lines for Disease Modeling of Hematopoietic and Immunological Diseases.

Authors:  Gülen Güney-Esken; Fatima Aerts-Kaya
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Front Immunol       Date:  2018-02-15       Impact factor: 7.561

Review 5.  Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.

Authors:  Faroogh Marofi; Heshu Sulaiman Rahman; Lakshmi Thangavelu; Aleksey Dorofeev; Favian Bayas-Morejón; Naghmeh Shirafkan; Navid Shomali; Max Stanley Chartrand; Mostafa Jarahian; Ghasem Vahedi; Rebar N Mohammed; Somayeh Shahrokh; Morteza Akbari; Farhad Motavalli Khiavi
Journal:  Stem Cell Res Ther       Date:  2021-03-22       Impact factor: 6.832

Review 6.  NK cell upraise in the dark world of cancer stem cells.

Authors:  Alireza Shokouhifar; Javad Firouzi; Masoumeh Nouri; Gholamreza Anani Sarab; Marzieh Ebrahimi
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

7.  Methods to Investigate miRNA Function: Focus on Platelet Reactivity.

Authors:  Alix Garcia; Sylvie Dunoyer-Geindre; Richard J Fish; Marguerite Neerman-Arbez; Jean-Luc Reny; Pierre Fontana
Journal:  Thromb Haemost       Date:  2020-10-29       Impact factor: 5.249

8.  Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease.

Authors:  Merel Stok; Helen de Boer; Marshall W Huston; Edwin H Jacobs; Onno Roovers; Trudi P Visser; Holger Jahr; Dirk J Duncker; Elza D van Deel; Arnold J J Reuser; Niek P van Til; Gerard Wagemaker
Journal:  Mol Ther Methods Clin Dev       Date:  2020-05-04       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.